Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6565-6572

  Gavrilov, Vladimir ^a   Lavrenkov, Konstantin ^b   Ariad, Samuel ^b   Shany, Shraga ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Cisplatin; Ionizing radiation; Non small cell lung cancer; Sodium valproate; Vinorelbine

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NAVELBINE; VALPROIC ACID; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; HISTONE DEACETYLASE INHIBITOR; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMORADIOTHERAPY; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; DNA DAMAGE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IONIZING RADIATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; RADIATION RESPONSE; TUMOR CELL CULTURE;

ANTICONVULSANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHEMORADIOTHERAPY; CISPLATIN; DNA DAMAGE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; RADIATION, IONIZING; TUMOR CELLS, CULTURED; VALPROIC ACID; VINBLASTINE;

EID: 84916199010     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. D'Addario G, Früh M, Reck M, Baumann P, Klepetko W and Felip E: Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO guidelines working group. Ann Oncol 21(suppl 5): v116-119, 2010.
2. Crino L, Weder W, van Meerbeeck J and Felip E: Early-stage and locally advanced (non-metastatic) non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO guidelines working group. Ann Oncol 21(suppl 5): v103-115, 2010.
3. Rengan R, Maity AM, Stevenson JP and Hahn SM: New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. Clin Cancer Res 17: 4192-4199, 2011.
4. Scotti V, Saieva C, Di Cataldo V, Bruni A, Desiden I, Bertocci S, Meattini I, Livi L, Simontacchi G, De Luca Cardillo C, Bendinelli B, Bastiani P, Mangoni M, Agresti B and Biti G: Vinorelbine-based chemoradiotherapy in non-small cell lung cancer. Tumori 98: 464-470, 2012.
5. Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H and Kudoh S: Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7: 1923-1930, 2008.
6. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP and Hershberger PA: Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 126: 743-755, 2010.
7. Zhang F, Zhang T, Teng ZH, Zhang R, Wang JB and Mei QB: Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 8: 823-831, 2009.
8. Blaheta RA, Michaelis M, Driever PH and Cinatl J Jr.: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25: 383-397, 2005.
9. 3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells. J Steroid Biochem Mol Biol 121: 391-394, 2010.
10. Van Nifteric KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P and Stalpers LJ: Valproic acid sensitizes human glioma cells for temozolomide and ã-radiation. J Neurooncol 107: 61-67, 2012.
11. Kueng W, Silber E and Eppenberger U: Quantification of cells cultured on 96-well plates. Anal Biochem 182: 16-19, 1989.
12. Liao W-C, Herman K, Zhao Z, Stoesz S and Campos-Gonzalez R: Development of a novel cell-based ELISA for analysis of intracellular proteins or phosphorylation of signaling molecules, 2010. Available at: http://www.biotechniques.com/multimedia/archive/00106/003-R-D-106345a.pdf
13. Kinner A, Wu W, Staudt C and Iliakis G: γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-5694, 2008.
14. Jackson SP: The DNA-damage response: new molecular insights and new approaches to cancer therapy. Biochem Soc Trans 37: 483-494, 2009.
15. Frankenberg-Schwager M: Review of repair kinetics for DNA damage induced in eukaryotic cells in vitro by ionizing irradiation. Radiother Oncol 14: 307-320, 1989.
16. Groselj B, Sharma NL, Hamdy FC, Kerr M and Kiltie AE: Histone deacetylase inhibitors as radisensitisers: effects on DNA damage signalling and repair. Br J Cancer 108: 748-754, 2013.
17. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A and Willems L: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 15: 2818-2828, 2009.
18. Smith J, Tho LM, Xu N and Gillespie DA: The ATM-CHK2 and ATR-CHK1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108: 73-112, 2010.
19. Chiu WH, Luo SJ, Chen CL, Cheng JH, Hsieh CY, Wang CY, Huang WC, Su WC and Lin CF: Vinca alkaloids cause aberrant ROS-mediated JNK activation, MCL-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. Biochem Pharmacol 83: 1159-1171, 2012.
20. Le HV, Minn AJ and Massagué J: Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells. J Biol Chem 280: 32018-32025, 2005.